Vestal Point Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Vestal Point Capital’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$24.9M	Hold	40,000	–	–	0.58%	41
2026 Q1	$30.9M	Buy	+40,000	New	+$30.6M	0.86%	39
2025 Q4	–	Sell	-25,000	Closed	-$14.1M	–	102
2025 Q3	$14.1M	Buy	+25,000	New	+$14.1M	0.63%	48
2025 Q1	–	Sell	-20,000	Closed	-$14.2M	–	78
2024 Q4	$14.2M	Buy	+20,000	New	+$16.8M	0.84%	36
2024 Q1	–	Sell	-10,000	Closed	-$8.78M	–	71
2023 Q4	$8.78M	Buy	+10,000	New	+$8.23M	0.93%	27

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Vestal Point Capital's REGN Position: Q2 2026 in Review

Vestal Point Capital held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 40,000 shares worth $24.9M. The position accounts for 0.58% of the portfolio, ranked #41.

Vestal Point Capital first reported a position in REGN in Q4 2023 and has held it in 5 quarters since. The position peaked at $30.9M in Q1 2026. 1,340 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Vestal Point Capital held 40,000 shares of Regeneron Pharmaceuticals worth $24.9M as of Q2 2026.
Vestal Point Capital left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
Regeneron Pharmaceuticals made up 0.58% of Vestal Point Capital's portfolio in Q2 2026, its #41 holding.
Vestal Point Capital first reported a position in Regeneron Pharmaceuticals in Q4 2023 and has held it in 5 quarters since.
Vestal Point Capital's Regeneron Pharmaceuticals position peaked at $30.9M in Q1 2026.
1,340 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Vestal Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.